For recurrent HNSCC, two therapeutic anti-PD-1 antibodies are currently used: Nivolumab after cisplatin failure without PD-L1 expression as a biomarker and Pembrolizumab after cisplatin failure and with a TPS ≥50%. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.